Untitled-1
  • HOME
  • COMPANY
    • Research
    • Scientific Advisors
  • TECHNOLOGY
    • TCR-T Cell
    • Clinical Application
  • PIPELINE
  • RESOURCES
    • News
    • Publications
    • Events
  • CONTACT

Dr. Antonio Bertoletti presents Lion TCR T-cell therapy at the International Society for Cellular Therapy Conference 2016

January 25, 2017Eventsinfo@liontcr.com

Dr. Antonio Bertoletti, was invited to speak at International Society for Cellular Therapy (ISCT) Conference 2016 hosted in Singapore on 26th May 2016. The title of his presentation was ‘Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus’. Dr. Bertoletti presented that HBV antigens can act as tumor-specific antigens in HBV-related HCC, and that our engineered TCR-T cells could recognize and lyse such tumor cells. He further presented our latest clinical results in treating liver transplant patients with chemotherapy-resistant HCC metastases.

http://www.isct2016.com/feature-session-challenging-cancer-diverse-immunotherapy-approaches-from-asia-joint-session-with-acto/

Previous post New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Next post Scientific Director, Dr. Sarene Koh, speaks at the 1st Transmed-VN Conference

News

  • Events
  • Press Release
  • Research

LION TCR

Proteos, 61 Biopolis Drive, Singapore 138673

T: +65 6586 9633


Facebook

FOR INQUIRIES

General
info@liontcr.com

Clinical Trials
clinicaltrials@liontcr.com

_

Investors
investors@liontcr.com

Career
career@liontcr.com

© 2017 All rights reserved | Terms and Conditions | Privacy Policy